Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Infectious Diseases

Topics

Biology

Epidemiology

Medicine

Internal Medicine

Gastroenterology

Show all topics

DOI

10.1016/s1473-3099(15)70099-x